Concord Drugs (BOM:538965) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Concord Drugs LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Concord Drugs's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

Concord Drugs's long-term debt to total assets ratio stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Concord Drugs LT-Debt-to-Total-Asset Historical Data

The historical data trend for Concord Drugs's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concord Drugs LT-Debt-to-Total-Asset Chart

Concord Drugs Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.02

0.08

0.03

Concord Drugs Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	0.03	-	0.04	-

Concord Drugs LT-Debt-to-Total-Asset Calculation

Concord Drugs's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

LT Debt to Total Assets (A: Mar. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2023 )	/	Total Assets (A: Mar. 2023 )
	=	19.113	/	582.31
	=	0.03

Concord Drugs's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	0	/	0
	=

Concord Drugs (BOM:538965) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Concord Drugs LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Concord Drugs's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Concord Drugs (BOM:538965) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Concord Drugs Ltd (BOM:538965) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

N/A

Address

3-11-451, L B Nagar, Hayatnagar Mandal, Hyderabad, TG, IND, 500074

Website

https://www.concorddrugs.in

Concord Drugs Ltd is an India based pharmaceutical company. The principal activity of the company is to manufacture licensed drugs based on the formulations approved. Its product portfolio includes Pharmaceutical Ready to fill Pellets, MUPS ((Multiple Unit Pellets System); Tissue Bio Adhesive; Injectables (Small Volume Parenterals); Capsules; Liquid Orals (Syrups & Suspensions); Dry Syrups (Powder) and Hand Sanitizers. Geographically, it operates only in India.

Concord Drugs (BOM:538965) Headlines

No Headlines